Leng Han, PhD

Dr. Han obtained his Ph.D. from Chinese Academy of Sciences and did postdoc training with Dr. Joseph C. Wu at Stanford University, and Dr. Han Liang at MD Anderson Cancer Center. Dr. Han’s lab focused on harnessing big data for precision oncology. In the past several years, his labs contributed to RNA-targeted therapy, target therapy, and immunotherapy, and published several papers in high-profile journals, including Cancer Cell, Nature Metabolism, Nature Immunology, Nature Communications, The Innovation, Cell Systems, Cell Reports, Nucleic Acids Research, Genome Medicine, Journal of the National Cancer Institute. He has been invited to contribute reviews, commentary, and spotlight by multiple journals, including Nature Reviews Clinical Oncology, Nature Biotechnology, Trends in Genetics, Trends in Cancer, Trends in Molecular Medicine, Genome Medicine, and Oncogene. To date, he has published >160 peer-reviewed papers, with a total of > 20,000 citations (Google scholar, H-index = 64).

Full publications can be accessed at  Google Scholar

1. Zhang Y, Zhao Z, Huang LA, Liu Y, Yao J, Sun C, Li Y, Zhang Z, Ye Y, Yuan F, Nguyen TK, Garlapati NR, Wu A, Egranov SD, Caudle AS, Sahin AA, Lim B, Beretta L, Calin GA, Yu D, Hung MC, Curran MA, Rezvani K, Gan B, Tan Z^#, Han L^#, Lin C^#, Yang L^#. Molecular mechanisms of snoRNA-IL-15 crosstalk in adipocyte lipolysis and NK cell rejuvenation. Cell Metabolism, 2023. PMID: PMID: 37329887
2. Liu Y^#, Chen Y, Han L^#. Bioinformatics: Advancing biomedical discovery and innovation in the era of big data and artificial intelligence. The innovation Medicine, 2023. Highlighted on the cover.
3. Xun Z, Ding X, Zhang Y, Zhang B, Lai S, Zou D, Zheng J, Chen G, Su B, Han L^#, Ye Y^#. Reconstruction of the tumor spatial microenvironment along the malignant-boundary-nonmalignant axis. Nature Communications, 2023. PMID: 36806082
4. Dong Y, Gao Q, Chen Y, Zhang Z, Du Y, Liu Y, Zhang G, Li S, Wang G, Chen X, Liu H, Han L^#, Ye Y^#, Identification of CircRNA signature associated with tumor immune infiltration to predict therapeutic efficacy of immunotherapy. Nature Communications, 2023, 14: 2540. PMID: 37137884
5. Liu Y^#, Han L^#. Harnessing transposable elements for cancer therapy. Trends in Cancer, 2023, PMID: 37248150
6. Chen C^#, Han L^#. Multi-omic genetic scores advance disease research. Trends in Genetics, 2023, PMID: 37295977
7. Chen Y^#, Liu Y, Han L^#. Spatial landscape of the tumor immune microenvironment. Trends in Cancer, 2033, PMID: 36967255
8. Yang J^#, Chen Y, Han L^#. A multi-omics perspective of CART T Cell therapy. Clinical Translational Medicine, 2023. PMID: 37228183
9. Yang J, Chen Y, Han L^#. Dynamic immune signatures as biomarkers for irAEs. Trends in Cancer, 2023, PMID: 36941187
10. Yang, J.^*, Chen, Y.^*, Jing, Y.^*, Green, M.R.^# and Han, L.^#. Advancing CAR T cell therapy through the use of multidimensional omics data. Nature Reviews Clinical Oncology, 2023, pp.1-18
11. Sun C^*, Ye Y^*, Tan Z^*, Liu Y, Li Y, Hu W, Liang K, Egranov SD, Huang LA, Zhang Z, Zhang Y, Yao J, Nguyen TK, Zhao Z, Wu A, Marks JR, Caudle AS, Sahin AA, Gao J, Gammon ST, Piwnica-Worms D, Hu J, Chiao PJ, Yu D, Hung MC, Curran MA, Calin GA, Ying H, Han L^#, Lin C^#, Yang L^#. Tumor-associated nonmyelinating Schwann cell-expressed PVT1 promotes pancreatic
    cancer kynurenine pathway and tumor immune exclusion. Science advances. 2023. 9(5):eadd6995
12.  Luo M^#, Han L^#. Autophagy induction sensitizes cancer cells to anti-cancer drugs. Autophagy. 2022.
13.  Jing Y^#, Yang J, Han L^#. Distinct T cell sub-clusters may serve as biomarkers for immune-related adverse events. Cell Reports Medicine. 2022. 4(1):100902.
14. Luo M*, Ye L*, Chang R*, Ye Y, Zhang Z, Liu C, Li S, Jing Y, Ruan H, Zhang G, He Y, Liu Y, Xue Y, Chen X^#, Guo AY^#, Liu H^#, Han L^#. Multi-omics characterization of autophagy-related molecular features for therapeutic targeting of autophagy. Nature Communications. 2022, 13: 6345. PMID: 36289218
15. Ruan H^#, Wang C, Han L^#. Characterization of circular RNAs with advanced sequencing technologies in human complex diseases. WIRES RNA, 2022: e1759, PMID: 36164985
16. Luo M, Liu Y, Hermida LC, Gertz, EM, Zhang Z, Li Q, Diao L, Ruppin E, and Han L^#, 2022. Race is a key determinant of the human intratumor microbiome. Cancer cell, 40(9), pp.901-902.
17. Liu Y^#,  Han L^# (2022). TRUST4 Interrogates the Immune Receptor Repertoire in Oncology and Immunotherapy. Cancer Immunology Research, OF1-OF1.
18. Jing Y*, Yang J*, Johnson DB#, Moslehi JJ#, Han L#. Harnessing big data to characterize immune-related adverse events. Nature Reviews Clinical Oncology 19, 269–280 (2022). 
19. Jing Y*, Chen X*, Li K, Liu Y, Zhang Z, Chen Y, Liu Y, Wang Y, Lin SH, Diao L, Wang J, Lou Y, Johnson DB, Chen X#, Liu H#, Han L#. Association of antibiotic treatment with immune-related adverse events in cancer patients receiving immunotherapy. Journal of Immunotherapy of Cancer (In press)
20. Zhang Z#,*, Luo M*, Li Q, Liu Y, Lussier C, Zhang J, Ye Y, Guo AY#, Han L#. Genetic, pharmacogenomic, and immune landscapes of enhancer RNAs across human cancers. Cancer Research (In press)
21. Ye Y*, Zhang Y*, Yang N*, Gao Q*, Ding X, Kuang X, Bao R, Zhang Z, Sun C, Zhou B, Wang L, Hu Q, Lin C, Gao J, Lou Y, Lin SH, Diao L, Liu H#, Chen X#, Mills GB#, Han L#. Profiling of immune features to predict immunotherapy efficacy. The Innovation, 2021
22. Jing Y#,*, Liu Y*, Li Q, Ye Y, Diao L, Huang Y, Zhou Y, Green MR, Mills GB, Han L#. Expression of chimeric antigen receptor therapy targets detected by single-cell sequencing of normal cells may contribute to off-tumor toxicity. Cancer Cell, 2021. PMID: 34678153
23. Zhang Z, Han L#. Circular RNAs sequenced at last. Nature Biotechnology. 2021. PMID: 33948001
24. Correa S#, Han L#. Career pathways, part 4. Nature Metabolism. 2021, 3: 446-448. PMID: 33824514
25. Ruan H#, Li Q, Liu Y, Liu Y, Lussier C, Diao L, Han L#. GPEdit: the genetic and pharmacogenomic landscape of A-to-I RNA editing in cancers. Nucleic Acids Research. 2021. gkab810. PMID: 34534336
26. Jing Y*, Zhang Y*, Wang J*, Li K*, Chen X, Heng J, Gao Q, Ye Y, Zhang Z, Liu Y, Lou Y, Lin SH, Diao L, Liu H#, Chen X#, Mills GB#, Han L#. Association between sex and immune-related adverse events during immune checkpoint inhibitor therapy. Journal of National Cancer Institute, 2021. PMID:33705549
27. Zhang Z, Jing , Ye Y, Chen Z, Jing Y, Li S, Hong W, Ruan H, Liu Y, Hu Q, Wang J, Li W, Lin C, Diao L#, Zhou Y#, Han L#.  Characterization of the dual functional effects of heat shock proteins (HSPs) in cancer hallmarks to aid development of HSP inhibitors. Genome Medicine, 2020, 12: 101. PMID: 33225964
28.  Zhang Z#, Hong W, Ruan H, Jing Y, Li S, Liu Y, Wang J, Li W, Diao L#, Han L#: HeRA: an atlas of enhancer RNAs across human tissues. Nucleic Acids Research, 2020, gkaa940, PMID: 33119754
29. Jing Y, Liu J, Ye Y, Pan L, Deng H, Wang Y, Yang Y, Diao L, Lin SH, Mills GB, Zhuang G#, Xue X#, Han L#. Multi-omics prediction of immune-related adverse events during checkpoint immunotherapy. Nature Communications, 2020, 11: 4946, PMID: 33009409
30. Liu Y, Ruan H, Li S, Ye Y, Hong W, Gong J, Zhang Z, Jing Y, Zhang X#, Diao L#, Han L#. The genetic and pharmacogenomic landscape of snoRNAs in human cancer. Molecular Cancer, 2020, 19: 108, PMID: 32576192
31. Ye Y, Jing Y, Li L, Mills GB, Diao L#, Liu H#, Han L#. Sex-associated molecular differences for cancer immunotherapy. Nature Communications, 2020, 11: 1779, PMID: 32286310
32. Ye Y, Zhang Z, Liu Y, Diao L#, Han L#: A Multi-Omics Perspective of Quantitative Trait Loci in Precision Medicine. Trends in Genetics, 2020, 36: 318-336, PMID: 32294413 (Feature review)
33. Li S#, Zhang Z, Han L#: 3D Spheroids Propel Tumor Characterization. Trends in Cancer, 2020, PMID: 32423684
34. Zhang Z, Lee JH, Ruan H, Ye Y, Krakowiak J, Hu Q, Xiang Y, Gong J, Zhou B, Wang L, Lin C, Diao L, Mills GB, Li W#, Han L#. Transcriptional landscape and clinical utility of enhancer RNAs for eRNA-targeted therapy in cancer. Nature Communications, 2019, 10: 4562. PMID: 31594934
35. Li S, Zhang Z, Han L#: Molecular Treasures of Cancer Cell Lines. Trends in Molecular Medicine, 2019 PMID: 31255475
36. Li S, Han L: Circular RNAs as promising biomarkers in cancer: detection, function, and beyond. Genome Medicine, 2019, 11:15. PMID:
    30894216
37. Zhang Z, Lee JH, Ruan H, Ye Y, Krakowiak J, Hu Q, Xiang Y, Gong J, Zhou B, Wang L, Lin C, Diao L, Mills GB, Li W#, Han L#. Transcriptional landscape and clinical utility of enhancer RNAs for eRNA-targeted therapy in cancer. Nature Communications, 2019, 10: 4562. PMID: 31594934
38. Ruan H, Xiang Y, Ko J, Li S, Jing Y, Zhu X, Ye Y, Zhang Z, Mills T, Feng J, Liu CJ, Jing J, Cao J, Zhou B, Wang L, Zhou Y, Lin C, Guo AY, Chen X, Diao L, Li W, Chen Z, He X, Mills GB, Blackburn MR, Han L#. Comprehensive characterization of circular RNAs in ~1000 human cancer cell lines. Genome Medicine, 2019, 11: 55. PMID: 31446897
39. Hong W, Ruan H, Zhang Z, Ye Y, Liu Y, Li S, Jing Y, Zhang H, Diao L, Liang H, Han L#. APAatlas: decoding alternative polyadenylation across human tissues. Nucleic Acids Research. 2019. PMID: 31586392
40. Ye Y, Hu Q, Chen H, Liang K, Yuan Y, Ruan H, Zhang Z, Song A, Zhang H, Liu L, Diao L, Lou Y, Zhou B, Wang L, Zhou S, Gao J, Jonasch E, Lin S, Xia Y, Lin C, Yang L#, Mills GB#, Liang H#, Han L#: Characterization of Hypoxia-associated Molecular Features to Aid Hypoxia-Targeted Therapy. Nature Metabolism, 2019, 1: 431-444. PMID: 31984309
41. Hu Q, Ye Y, Chan LC, Liang K, Li Y, Evans K, Pan Y, Zhang Y, Xia W, Liu J, Gong J, Chatterjee S, Han L#, Lin C#, Yang L#: Oncogenic LncRNA Downregulates Cancer Cell Antigen Presentation and Intrinsic Tumor Suppression. Nature Immunology, 2019 PMID: 31160797
42. Xiang Y, Ye Y, Zhang Z, Han L#: Maximizing the utility of cancer transcriptomic data. Trends in Cancer, 2018, 4:823-837. PMID: 30470304
43. Gong J, Wan H, Mei S, Ruan H, Zhang Z, Liu C, Guo AY, Diao L#, Miao X#, Han L#: Pancan-meQTL: a database to systematically evaluate the effects of genetic variants on methylation in human cancer. Nucleic Acids Research, 2018, gky814
44. Ye Y, Xiang Y, Ozguc FM, Kim Y, Liu CJ, Park PK, Hu Q, Diao L, Lou Y, Lin C, Guo AY, Zhou B, Wang L, Chen Z, Takahashi JS, Mills GB, Yoo SH, Han L#: The genomic landscape and pharmacogenomic interactions of clock genes in cancer chronotherapy. Cell Systems, 2018, 6: 314-328 
45. Gong J, Li Y, Liu CJ, Xiang Y, Li C, Ye Y, Zhang Z, Hawke DH,  Park PK, Diao L, Putkey JA, Yang L, Guo AY#, Lin C#, Han L#: A pan-cancer analysis of the expresion and clinical relevance of small nucleolar RNA in human cancer. Cell Reports, 2017, 21: 1968-1981 
46. Xiang Y, Ye Y, Lou Y, Yang Y, Cai C, Zhang Z, Mills T, Chen NY, Kim Y, Ozguc FM, Diao L, Karmouty-Quintana H, Xia Y, Blackburn M, Kellems R, Chen Z, Yoo SH, Shyu AB, Mills GB, Han L#: Comprehensive characterization of alternative polyadenylation in human cancer. Journal of the National Cancer Institute, 2017, djx223
47. Gong J, Mei S, Liu C, Xiang  Y,Ye Y, Zhang Z, Feng J, Liu R, Diao L, Guo AY, Miao X, Han L#: PancanQTL: systematic identification of cis-eQTLs and trans-eQTLs in 33 cancer types. Nucleic Acids Research, 2017, gkx861
48. Gong J, Liu C, Liu W, Xiang Y, Diao L, Guo AY#, Han L#: LNCediting: a database for functional effects of RNA editing in lncRNAs. Nucleic Acid Research. 2016, gkw835 
49. Han L, Diao L, Yu S, Xu X, Li J, Zhang R, Yang Y , Werner HM, Eterovic KA, Yuan Y, Li J, Nair N, Minelli R, Tsang Y, Cheung LW, Jeong KJ, Roszik J, Ju Z, Woodman S, Lu Y, Scott KL, Li JB, Mills GB, Liang H: The genomic landscape and clinical relevance of A-to-I RNA editing in human cancers. Cancer Cell, 2015, 28: 515-528.